Improvements in and Relating to Analysis (Various Sampling Capture Methods)

Technology #ua11-067

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Frederic Zenhausern
Director, COM-PHX Applied NanoBioscience & Medicine
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Background:  Rapid DNA testing will apply to DNA forensics, food analysis, medical diagnostics, animal testing, security and homeland applications.


Invention:  A circuit board for interfacing with a sample cartridge, wherein the sample cartridge comprises a working surface defining a plurality of sections for processing a sample; wherein the circuit board is configured to be adjacent the working surface in use and comprises:  a plurality of element, each of the plurality of elements is associated with one of the plurality of sections and is arranged to be positioned adjacent the associated one of the plurality of sections in use; and wherein the circuit further delimits at least one alignment feature for engaging a corresponting alighment feature on the cartridge and ensuring that the plurality of elements are positioned adjacent the associated one of the plurality of sections in use.


Advantages:  Allows for automation of processing of a sample.  Sample cartridge provides a plurality of sections and the circuit board enables the sections to be activated as required for processing the sample.  In short, the system is potentially user-friendly, low cost, and is polymer-based electronic and fluidic devices that are designed to simplify the processes of running various molecular diagnostic tests.


Markets:  Molecular diagnostics market is being driven by several growth factors, which include the need for automated and easy-to-handle techniques, which combine optimized sample preparation, analysis, and data evaluation, and the growing availability of molecular diagnostic tests for monitoring the therapeutic efficacy of expensive drugs. Additionally, the requirement of swift diagnoses techniques that would diagnose disease condition and medical disorders quickly and offer a strong and consistent tool for quick therapy decisions represents the other key factor. In terms of technological push, genomics and proteomics are the major drivers of the molecular diagnostic market. Nanobiotechnology and biochips are also expected to drive future growth.


World molecular diagnostics market is poised to deliver strong double-digit annual growth over the next several years. Global market size, as measured in terms of dollars, is expected to reach $6.35 billion by the year 2015. United States represents the largest market, accounting for a 42.75% share estimated in the year 2008. Europe represents the second largest market, distantly followed by Japan, as stated by Global Industry Analysts, Inc. Market for infectious disease testing in Europe is projected to reach $1.02 billion by the year 2012. Opportunities for growth exists in emerging segments of pharmacogenomics and cancer screening, both of which are forecast to grow at a CAGR of 11.05% and 10.71% respectively over the period 2011 through 2015.


Leading players operating in the market include Abbott Laboratories, Applera Corporation, bioMérieux, CytoCore Inc, GE Healthcare, Gen-Probe Inc, Genzyme Corporation, Nanogen, Novartis Vaccines & Diagnostics Inc., QIAGEN N.V, Digene Corporation, Quest Diagnostics Inc., Roche Diagnostics, Siemens Healthcare Diagnostics, and Tecan Group Ltd, among others. [Source:  “Molecular Diagnostics: A Global Strategic Business Report” published by Global Industry Analysts, Inc., April 2008, MCP-1226].


Status:  The work is continuing on this product development research.  The University of Arizona?s Center for Applied NanoBioscience and Medicine.  The University of Arizona is looking for strategic partners to realize a fully functionalized, alpha-system to demonstrate completely smart molecular diagnostic platforms, fully leveraging the advances that have been made in the fields of genomics, microfluidics and nanotechnology.


Lead Investigator:  Frederic E. Zenhausern

UA ID:  UA11-067